Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PI4KA | P42356 | 1/20 | 0.57 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.57 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.57 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | PRMT5 | O14744 | 3/20 | 0.44 |
| ▸ | WDR77 | Q9BQA1 | 3/20 | 0.44 |
| ▸ | ADK | P55263 | 2/20 | 0.43 |
| ▸ | METTL3 | Q86U44 | 1/20 | 0.43 |
| ▸ | METTL14 | Q9HCE5 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21089761 | 1.00 | PI4KA (0.57) | PI4KAPI4K2BPI4K2API4KBALDH1A1 | |
| SCHEMBL18026201 | 0.90 | PI4KA (0.45) | PI4KAPI4K2BPI4K2API4KBPRMT5 | |
| SCHEMBL18009834 | 0.88 | PI4KA (0.58) | PI4KAPI4K2BPI4K2API4KBALDH1A1 | |
| SCHEMBL18009818 | 0.88 | PI4KA (0.58) | PI4KAPI4K2BPI4K2API4KBALDH1A1 | |
| SCHEMBL25956503 | 0.87 | RXFP1 (0.44) | PI4KAPI4K2BPI4K2API4KBPRMT5 | |
| SCHEMBL22334076 | 0.87 | PI4KA (0.69) | PI4KAPI4K2BPI4K2API4KBPRMT5 | |
| SCHEMBL22434784 | 0.87 | PI4KA (0.69) | PI4KAPI4K2BPI4K2API4KBPRMT5 | |
| SCHEMBL22334075 | 0.87 | PI4KA (0.69) | PI4KAPI4K2BPI4K2API4KBPRMT5 | |
| SCHEMBL15397029 | 0.87 | PI4KA (0.69) | PI4KAPI4K2BPI4K2API4KBPRMT5 | |
| SCHEMBL22002267 | 0.86 | PI4KA (0.42) | PI4KAPI4K2BPI4K2API4KBPRMT5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3585904-B1 | USE OF BIOMARKERS IN IDENTIFYING CANCER PATIENTS THAT WILL BE RESPONSIVE TO TREATMENT WITH A PRMT5 INHIBITOR | JANSSEN PHARMACEUTICA NV (BE) | 2023-11-29 | — | — | EP | disclosed |
| US-20230330127-A1 | 6-6 BICYCLIC AROMATIC RING SUBSTITUTED NUCLEOSIDE ANALOGUES FOR USE AS PRMT5 INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2023-10-19 | — | — | US | disclosed |
| WO-2023152709-A1 | RNA POLYMERASE INHIBITORS AND METHODS USING SAME | ARBUTUS BIOPHARMA CORPORATION (CA) | 2023-08-17 | — | — | WO | disclosed |
| EP-4219496-A1 | NOVEL 6-6 BICYCLIC AROMATIC RING SUBSTITUTED NUCLEOSIDE ANALOGUES FOR USE AS PRMT5 INHIBITORS | JANSSEN Pharmaceutica NV (BE) | 2023-08-02 | — | — | EP | disclosed |
| US-20220205026-A1 | Use of Biomarkers in Identifying Cancer Patients That Will Be Responsive to Treatment With a PRMT5 Inhibitor | JANSSEN PHARMACEUTICA NV (BE) | 2022-06-30 | — | — | US | disclosed |
| US-11318157-B2 | 6-6 bicyclic aromatic ring substituted nucleoside analogues for use as PRMT5 inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2022-05-03 | — | — | US | disclosed |
| EP-3341368-B1 | NOVEL 6-6 BICYCLIC AROMATIC RING SUBSTITUTED NUCLEOSIDE ANALOGUES FOR USE AS PRMT5 INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2021-10-06 | — | — | EP | disclosed |
| EP-3426664-B1 | SUBSTITUTED NUCLEOSIDE ANALOGUES FOR USE AS PRMT5 INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2021-06-30 | — | — | EP | disclosed |
| US-20210070798-A1 | Inhibitors of E1 activating enzymes | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-03-11 | — | — | US | disclosed |
| US-20200369667-A1 | HETEROCYCLIC COMPOUNDS AS PRMT5 INHIBITORS | ANGEX PHARMACEUTICAL, INC. | 2020-11-26 | — | — | US | disclosed |
| WO-2016178870-A1 | 5'-SUBSTITUTED NUCLEOSIDE ANALOGS | ELI LILLY AND COMPANY (US) | 2016-11-10 | — | — | WO | disclosed |
| WO-2016135582-A1 | SUBSTITUTED NUCLEOSIDE DERIVATIVES USEFUL AS ANTICANCER AGENTS | PFIZER INC. (US) | 2016-09-01 | — | — | WO | disclosed |
| US-20160244475-A1 | SUBSTITUTED NUCLEOSIDE DERIVATIVES USEFUL AS ANTICANCER AGENTS | PFIZER INC. (US) | 2016-08-25 | — | — | US | disclosed |
| US-20160194348-A1 | SUBSTITUTED PYRROLO[2,3-D]PYRIMIDINES | MILLENNIUM PHARM INC (US) | 2016-07-07 | — | — | US | disclosed |
| US-20140256668-A9 | SUBSTITUTED PYRROLO]2,3-D]PYRIMIDINES | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2014-09-11 | — | — | US | disclosed |
| US-20130338094-A1 | SUBSTITUTED PYRROLO]2,3-D]PYRIMIDINES | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2013-12-19 | — | — | US | disclosed |
| EP-1848718-B1 | INHIBITORS OF E1 ACTIVATING ENZYMES | MILLENNIUM PHARM INC (US) | 2012-08-01 | — | — | EP | disclosed |
| US-20110136834-A1 | INHIBITORS OF E1 ACTIVATING ENZYMES | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-06-09 | — | — | US | disclosed |
| US-7951810-B2 | Substituted pyrrolo[2,3-d]pyrimidines as inhibitors of E1 activating enzymes | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-05-31 | — | — | US | disclosed |
| US-20060189636-A1 | Inhibitors of E1 activating enzymes | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2006-08-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11318157-B2 | 6-6 bicyclic aromatic ring substituted nucleoside analogues for use as PRMT5 inhibitors | PRMT5, PRMT6, PRMT1 | PI4KA 2914/4885PI4K2B 3149/4885PI4K2A 3334/4885 |
| US-20160244475-A1 | SUBSTITUTED NUCLEOSIDE DERIVATIVES USEFUL AS ANTICANCER AGENTS | TYMP, NME1, PNP | PI4KA 989/4885PI4K2B 1184/4885PI4K2A 1232/4885 |
| US-20110136834-A1 | INHIBITORS OF E1 ACTIVATING ENZYMES | ECE1, RNASE1, RCE1 | PI4KA 1991/4885PI4K2B 2891/4885PI4K2A 2431/4885 |
| US-20200369667-A1 | HETEROCYCLIC COMPOUNDS AS PRMT5 INHIBITORS | PRMT5, PRMT1, PRMT6 | PI4KA 2266/4885PI4K2B 2258/4885PI4K2A 2575/4885 |
| US-20230330127-A1 | 6-6 BICYCLIC AROMATIC RING SUBSTITUTED NUCLEOSIDE ANALOGUES FOR USE AS PRMT5 INHIBITORS | PRMT5, PRMT6, PRMT1 | PI4KA 2674/4885PI4K2B 2552/4885PI4K2A 2966/4885 |
| US-20140256668-A9 | SUBSTITUTED PYRROLO]2,3-D]PYRIMIDINES | DPYD, CCND3, POLD3 | PI4KA 1546/4885PI4K2B 704/4885PI4K2A 804/4885 |
| US-20160194348-A1 | SUBSTITUTED PYRROLO[2,3-D]PYRIMIDINES | TYMP, TYMS, PPA1 | PI4KA 1455/4885PI4K2B 2027/4885PI4K2A 1655/4885 |
| US-20210070798-A1 | Inhibitors of E1 activating enzymes | ECE1, RNASE1, RCE1 | PI4KA 1991/4885PI4K2B 2891/4885PI4K2A 2431/4885 |
| US-20130338094-A1 | SUBSTITUTED PYRROLO]2,3-D]PYRIMIDINES | DPYD, CCND3, POLD3 | PI4KA 1546/4885PI4K2B 704/4885PI4K2A 804/4885 |
| US-20060189636-A1 | Inhibitors of E1 activating enzymes | ECE1, RNASE1, RCE1 | PI4KA 1991/4885PI4K2B 2891/4885PI4K2A 2431/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.